Clinical trials
Locally Advanced Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting locally advanced gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 130 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07221149RecruitingPhase 2/Phase 3
Pumitamig vs Nivolumab for untreated stomach or esophagus cancer
This trial compares two treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combination works better.
Phoenix, ArizonaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT07315750RecruitingPhase 3
Study of three drugs vs standard care for HER2-high stomach cancer
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
Beijing, BJ-BeijingAges 18–75 - NCT07315854RecruitingPhase 2
Immunotherapy combo plus chemo for untreated stomach cancer
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Mobile, AlabamaAges 18 years+ - NCT07385703RecruitingPhase 3
A trial of LM-302 with tislelizumab for stomach cancer
This trial tests a new drug combination for stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if adding LM-302 to standard treatments helps people whose tumors have a specific protein called CLDN18.2.
Hefei, AnhuiAges 18 years+ - NCT07518147RecruitingPhase 3
BL-M05D1 for advanced stomach cancer after first treatment
This study tests a new antibody drug (BL-M05D1) for advanced stomach or lower esophagus cancer that did not respond to first-line chemotherapy. The drug targets a protein called claudin 18.2 found on some cancer cells and may help slow or shrink the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT07655024RecruitingPhase 2
TAIC plus FOLFOX for advanced stomach cancer
This trial tests a traditional Chinese medicine (TAIC) combined with chemotherapy (FOLFOX) for people with advanced stomach or gastroesophageal junction cancer that can't be removed with surgery. It aims to see if the combination can help shrink the tumor and improve survival.
BeijingAges 18 years+ - NCT07356466Enrolling by invitationEarly Phase 1
Combination therapy vs. standard chemo for advanced stomach cancer
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Fuzhou, FujianAges 18–75 - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Santa Rosa, CaliforniaAges 18 years+ - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Anchorage, AlaskaAges 18 years+ - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT07689851RecruitingPhase 2
Chemoradiotherapy plus an immunotherapy for advanced gastric cancer
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
Shenzhen, GuangdongAges 18–75 - NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06532006RecruitingPhase 3
HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Anaheim, CaliforniaAges 18 years+ - NCT06496789RecruitingPhase 2
Immunotherapy plus chemo before surgery for stomach cancer
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
TianjinAges 18–75 - NCT05813015RecruitingPhase 3
Testing S-1 after stomach cancer surgery with or without sequence therapy
This Phase 3 study compares two ways of giving S-1 medicine after curative stomach cancer surgery in stage III disease. It aims to see whether the sequential approach improves outcomes while keeping treatment safe.
Hanzhou, ZhejiangAges 18–75 - NCT06506292RecruitingPhase 2
Study of adebrelimab plus chemo before and after stomach cancer surgery
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT05593458RecruitingPhase 3
Stomach cancer surgery before chemo: artery-based or drip chemo
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
Hangzhou, ZhejiangAges 18–75
Hear when a new Locally Advanced Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 130 recruiting locally advanced gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.